Product Datasheet

ZN-c3

Catalog No. **BP-02003** · CAS **2376146-48-2** · Form **free base** · Physical state **solid** · Color **Light yellow to yellow** · Version **1.0** · Revision **2026-09-10**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
Wee1	**Cancer**

Molecular formula	$C_{29}H_{34}N_8O_2$
Molecular weight	**526.6327**

STRUCTURE



DESCRIPTION

ZN-c3 (Azenosertib) is an orally active, highly potent and selective Wee1 inhibitor (IC50=3.9 nM). ZN-c3 can be used for the research of cancer.

BIOLOGICAL ACTIVITY

In Vitro

Azenosertib inhibits proliferations of cancer cells H23 and A427 with IC50s 103 and 75 nM.

In Vivo

Azenosertib (80 mg/kg; p.o.; 28 days) inhibits tumor growth in A427 xenograft NOD/SCID mice model.

Azenosertib (10 mg/kg, p.o.) shows plasma exposure Cmax of 2.1 μM, a half-time T1/2 of 2.3 h, an AUC0-24 h of 9.7 μM·h, and an oralbioavailability of F=142% in beagle dog model.

SOLUBILITY

Soluble in DMSO 175 mg/mL

REFERENCES

[1]. Meng, Xiangbing et al. “Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 Mutations. Frontiers in medicine vol. 8 737951. 4 Oct. 2021, doi:10.3389/fmed.2021.737951

[2]. Huang, Peter Q et al. “Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer. Journal of medicinal chemistry vol. 64,17 (2021): 13004-13024. doi:10.1021/acs.jmedchem.1c01121